JINLING PHARM.(SZ:000919) Shen Zhen Shang Bao·2026-01-20 15:44Group 1 - The core project of Jinling Pharmaceutical, which involves the construction of a common production platform for core raw materials and high-end pharmaceutical intermediates, has its completion date postponed from March 2026 to March 2028, a delay of 24 months [1] - The project is expected to utilize a total of 100 million yuan in raised funds, but as of September 30, 2025, only 2.57% of the investment has been made, amounting to 256.99 thousand yuan [1] - The company has raised a total of 750 million yuan through a specific stock issuance, with a net amount of 743 million yuan, of which 144 million yuan is budgeted for the raw material project [1] Group 2 - As of September 30, 2025, the company has a balance of 729 million yuan in raised funds, with 680 million yuan allocated for cash management, indicating an idle rate of over 93% [2] - The company asserts that the delay complies with regulatory requirements and does not harm shareholder interests, yet the slow progress of investment projects and prolonged idle funds have raised market concerns [2]